Most of these urticarias occur within minutes of provocation, and resolve within 2 hours, with the exception of delayed-pressure urticaria and dermographism which may persist for 24 hours or longer.

In two clinical studies, Dupixent showed reductions in itch severity and urticaria activity at 24 weeks, as well as an increased likelihood of well-controlled disease or complete response at 24 ...

TOKYO, May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of ...

16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO, May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO ...

The CUPID A and CUPID C trials reported a two-thirds reduction in itch and urticaria activity scores at week 24. Dupilumab's safety profile is well-established, contrasting with safety concerns of ...

Unlike the flat patches often seen in lighter skin, atopic dermatitis in darker skin might cause small, raised bumps called papular eczema. These bumps may look like tiny pimples or rough patches ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain ...

Papular eczema, where the rash appears primarily as small, distinct bumps rather than confluent patches, occurs more commonly in individuals of African and Caribbean descent. These widespread ...

The US Food and Drug Administration (FDA) has granted approval to Dupixent or dupilumab for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents who are aged 12 years or ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

An exanthem is any eruptive skin rash that may be associated with fever or other systemic symptoms. Causes include infectious pathogens, medication reactions and, occasionally, a combination of ...